- Steven Brandes, Washington University
- Cosimo De Nunzio, Ospedale Sant'Andrea
- John Gearhart, Johns Hopkins Children's Center
- Jose Karam, MD Anderson Cancer Center
- Ercan Kocakoc, Bezmialem Vakif University
- Salvatore Micali, University of Modena and Reggio Emilia
- Alexander Parker, Mayo Clinic
- Charles J Rosser, University of Hawaii Cancer Center
- Philippe Spiess, Moffitt Cancer Center
- Mostafa Taymour, University of Cairo
- Hayley Henderson, BioMed Central
Early prostate-specific antigen (PSA) measurements following radical prostatectomy should aid risk stratification in men with positive surgical margins, and patients not likely to experience subsequent disease progression can be spared the toxicity of immediate adjuvant radiotherapy and thus, overtreatment.
Eva Gupta et al. review metastatic Castration Resistant Prostate Cancer (mCRPC) and the rationale for the newly approved hormonal treatments, and discusses ongoing trials that are being done to improve the efficacy of the approved agents for mCRPC.
Broad band, short-lasting antibiotic therapy in association with a nutritional supplement (serenoa repens, lactobacillus sporogens and arbutin) show better control and recurrence rate on patients affected by chronic bacterial prostatitits (CBP) in comparison with antibiotic treatment alone.
The International Index of Erectile Function (IIEF-5) may not represent a distinctive diagnostic tool to discriminate pathophysiological differences of ED, with higher IIEF-5 scores in men with pyschogenic related ED and no changes observed amongst men with different organic pathophysiologies.
BMC Urology 2014, 14:89
BMC Urology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of urological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
BMC Urology is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
BMC series blog
- 20 November 2014
- GP chlamydia testing rates: previously unexplored associations
- 18 November 2014
- Measuring the impact of humanitarian assistance
- 06 November 2014
- Behind the image: Kyle Harrington
Section Editor Profile
Cosimo De Nunzio, MD, PhD, is Consultant Urologist and contract Professor at the Department of Urology, Ospedale Sant'Andrea, University "La Sapienza", Roma, Italy. His research focus is prostatic disorders with a particular interest in voiding dysfunction, Benign prostatic Hyperplasia and prostate cancer diagnosis and management.
"I am pleased to be involved with BMC Urology first as a reviewer and now as Section Editor for Voiding Dysfunction. BMC Urology is an open access journal publishing original peer-reviewed articles, currently 10th on the SCImago Journal & Country Rank table and with and increasing number of manuscripts published in the last 4 years. When I joined BMC Urology, I have been particularly impressed by the excellent group of Section and Associate Editors involved in the Editorial Board and notwithstanding their young age, they are extremely expert in their field of interest. The journal's excellent editorial staff and the rapidity of the peer review process is another crucial quality of this journal. Moreover, I strongly support the open access platform used by BMC Urology which makes the specialized knowledge of urology more widely available to the scientific community at large, independently of the institutional affiliation or economic resources."
News from the web
- 21 November 2014
- A combination of 2 existing anti-cancer drugs for kidney cancer shows good patient response
- 21 November 2014
- Ferroptosis, a novel form of non-apoptotic cell death, holds great therapeutic potential
- 19 November 2014
- Patients with advanced papillary kidney cancer respond well to a combination of two existing anti-cancer drugs